Shook, Hardy & Bacon Partners Rob Adams and Alicia Donahue speak at ACI’s 21st Annual Conference on Drug & Medical Device Litigation slated for December 5-7, 2016, in New York City.
Adams joins a panel discussing “The Rebirth of Daubert and Frye: Recent Successful Expert Challenges” that will review the benefits and challenges of presenting company witnesses in the Daubert and Frye context as well as offer practical tips for navigating unreliable expert testimony. The discussion will be moderated by Brennan Torregrossa, Vice President and Associate General Counsel of GlaxoSmithKline; other panelists will include Julie Fink, Senior Corporate Counsel at Pfizer.
Donahue joins Teva Pharmaceuticals Associate General Counsel Howard Cyr and others for a breakout session titled “Deep Dive into Women’s Health: Preparing for the Second Wave of Products Liability Litigation.” Among other things, the group will address evolving theories and themes related to the lack of scrutiny for women’s clinical trials, deceptive marketing targeted to women and the disproportionate number of adverse events that affect women.
Shook is a co-sponsor of the event.